CellGenix
CellGenix® is a Freiburg-based manufacturer of 62 GMP- and Preclinical-grade recombinant human cytokines and growth factors, supplying regulatory-compliant raw materials to cell and gene therapy developers worldwide via Sartorius AG.
- Company typePrivate
- Founded1994
- HeadquartersFreiburg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CellGenix does
CellGenix is a Freiburg, Germany-based manufacturer of high-purity recombinant human cytokines and growth factors sold as raw and ancillary materials to the cell and gene therapy industry. Founded in 1994 and operating with 51-100 employees, the company offers a portfolio of 62 specialized recombinant proteins spanning interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, Activin A, and TPO. Each SKU is offered in two quality grades — GMP (for further manufacturing use in clinical and commercial cell therapy production) and Preclinical (for preclinical ex vivo use) — with animal-component-free (51 SKUs) and xeno-free (10 SKUs) formulations to satisfy stringent regulatory requirements for Advanced Therapy Medicinal Products (ATMPs). Product specifications emphasize ultra-low endotoxin levels (e.g., ≤ 0.010 EU/µg and ≤ 0.025 EU/µg options), high purity (≥ 95% / ≥ 97%), and documented activity ranges, positioning CellGenix as a regulatory-grade supplier of critical raw materials.
CellGenix operates as a wholly-owned brand of Sartorius AG and is distributed exclusively through Sartorius's global e-commerce storefront (shop.sartorius.com) and enterprise field-sales channels, reaching cell and gene therapy manufacturers (CAR-T, NK cell, dendritic cell, iPSC/ESC, MSC, organoid, HSC developers), CDMOs, regenerative medicine companies, and academic/industrial life science researchers worldwide. Pricing is quote-based and not publicly disclosed, with standard pack sizes of 50 µg, 1 mg, and bulk formats (500 mL, 1000 mL). The company holds a registered CellGenix® trademark under Sartorius and competes on brand reputation, regulatory documentation depth, and domain specialization rather than on breadth of product categories. The founder, Felicia M Rosenthal, continues to serve as Co-founder, CEO & Managing Director.
CellGenix firmographics
Firmographics- Name
- CellGenix
- Website
- https://cellgenix.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CellGenix® is a Freiburg-based manufacturer of 62 GMP- and Preclinical-grade recombinant human cytokines and growth factors, supplying regulatory-compliant raw materials to cell and gene therapy developers worldwide via Sartorius AG.
- Ownership category
- akta.pro rank
CellGenix industry classification
Industry- Product category
- Cell Therapy Raw Materials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industry
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
Keywords
Where CellGenix is headquartered
LocationHeadquarters
- HQ city
- Freiburg
- HQ country
- Germany
- HQ region
- Europe
Markets served
CellGenix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Recombinant Protein Product Sales: CellGenix generates revenue through the sale of recombinant growth factors and cytokines to researchers and biopharmaceutical companies engaged in cell therapy, gene therapy, and regenerative medicine applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | GMP-grade products for clinical and commercial use |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
CellGenix product offering
Product offeringCore offering
CellGenix® manufactures and supplies 62 recombinant human growth factors and cytokines—including interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21, IL-1β), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, TPO, and Activin A—for use as raw and ancillary materials in cell and gene therapy manufacturing. Products are offered in both GMP (for further manufacturing use) and Preclinical (for preclinical ex vivo use) quality grades, with animal-component free and xeno-free formulations available, and are sold exclusively through the Sartorius distribution network.
Product overview
CellGenix® is a brand of recombinant human growth factors and cytokines for the cell and gene therapy market. The portfolio includes recombinant proteins such as interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, TPO, and Activin A. Products are available in GMP-grade (for further manufacturing use) and Preclinical-grade (for preclinical ex vivo use), targeting applications in cell and gene therapy, immune cell culture, stem cell biology, and regenerative medicine. The CellGenix® brand is distributed exclusively through Sartorius AG and focuses on xeno-free, animal-component-free formulations.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 62 specialized recombinant proteins available for cell and gene therapy applications
Companies that use CellGenix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
CellGenix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CellGenix partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SartoriuscoreCellGenix operates as a brand owned and distributed by Sartorius, a leading biopharmaceutical equipment and supplies company. All CellGenix products are sold through Sartorius's e-commerce platform and distribution network.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
CellGenix competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Privately held German life science company that supplies recombinant cytokines, cell culture reagents, and instruments for cell and gene therapy manufacturing, with deep direct overlap with CellGenix's product portfolio and target customers (CDMOs and biopharma cell therapy developers).
- Bio-Techne (R&D Systems): Publicly traded US supplier of recombinant proteins (R&D Systems brand) including GMP-grade cytokines and growth factors used in cell therapy, regenerative medicine, and research — directly competing with CellGenix across both preclinical and GMP tiers.
- STEMCELL Technologies: Canadian supplier of cell culture media, reagents, cytokines, and tools for stem cell research and cell therapy development, with comparable specialty focus and customer overlap (academic and commercial cell therapy researchers, regenerative medicine developers).
- Akron Biotechnology: US-based supplier of ancillary materials, cytokines, and media for cell and gene therapy manufacturing, including GMP-grade recombinant proteins — a direct peer in the cell therapy raw materials niche with similar customer use cases.
- FUJIFILM Irvine Scientific: Supplier of cell culture media, reagents, and ancillary materials for cell therapy and regenerative medicine (including recombinant proteins), competing with CellGenix for GMP raw material wallet share at CDMOs and biopharma cell therapy developers.
Broad incumbents
- Cytiva: Global bioprocess supplier (formerly GE Healthcare Life Sciences) offering cell culture media, single-use technologies, and process services used by cell therapy manufacturers; overlaps with CellGenix on cell therapy raw materials but at much broader scale.
- Peprotech (Thermo Fisher Scientific): Peprotech was a specialist cytokine supplier acquired by Thermo Fisher; now positioned within Thermo Fisher's broader bioproduction portfolio, offering GMP and research-grade recombinant proteins that compete head-to-head with CellGenix while leveraging Thermo Fisher's larger scale and distribution.
- Lonza Group: Global CDMO and bioproducts company offering cell therapy manufacturing services plus cell and gene therapy raw materials and media; competes with CellGenix through its own recombinant protein/media portfolio and its CDMO relationships.
Others
- CellGenix (as Sartorius brand) - Sartorius AG: Parent company/distribution channel that owns the CellGenix® brand and sells all products through shop.sartorius.com — included as a parent/strategic relationship rather than a competitor, but adjacent given Sartorius's broader bioprocess portfolio.
Emerging players
- Sino Biological: China-based supplier of recombinant proteins, antibodies, and reagents that has expanded into GMP-grade cytokines for cell therapy — an emerging competitor that could pressure pricing as Chinese cell therapy manufacturing scales.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CellGenix social profiles
Digital presenceCellGenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellGenix leadership team
Management profileNumber of profiles
Profiles1 record
CellGenix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellGenix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellGenix
What does CellGenix do?
CellGenix® manufactures and supplies 62 recombinant human growth factors and cytokines—including interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21, IL-1β), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, TPO, and Activin A—for use as raw and ancillary materials in cell and gene therapy manufacturing. Products are offered in both GMP (for further manufacturing use) and Preclinical (for preclinical ex vivo use) quality grades, with animal-component free and xeno-free formulations available, and are sold exclusively through the Sartorius distribution network.
Is CellGenix a public or private company?
CellGenix is a private company. It is classified as corporate owned and is currently operating.
When was CellGenix founded?
CellGenix was founded in 1994. It employs 51 to 100 people.
Where is CellGenix based?
CellGenix is headquartered in Freiburg, Germany, in the Europe region.
How does CellGenix make money?
One revenue line is on record: recombinant Protein Product Sales.
Who are CellGenix's main competitors?
Direct peers on record are Miltenyi Biotec, Bio-Techne (R&D Systems), STEMCELL Technologies, Akron Biotechnology and FUJIFILM Irvine Scientific. Broad incumbents are Cytiva, Peprotech (Thermo Fisher Scientific) and Lonza Group. CellGenix (as Sartorius brand) - Sartorius AG is listed as an others. Sino Biological is listed as an emerging player.
Does CellGenix have an API?
No public API is recorded for CellGenix.
What industry is CellGenix in?
CellGenix's product category is Cell Therapy Raw Materials. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 325414 and its SIC code is 2836.